Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare

GQ1010 preclinical profile demonstrates potential for differentiation vs other TROP2 ADCs Proprietary GeneQuantum platform provides single-step site-specific enzymatic conjugation and potential for superior linker-payload technology vs conventional ADCs BRIDGEWATER, N.J., April 13, 2023…